Table 1 Basic demographic and clinical information of the study population.
N = 530 | |
|---|---|
Age | 81.93 ± 10.9 |
Female gender | 260 (49.1) |
Medical History | |
CAD/CHF | 238 (44.9) |
COPD/asthma | 66 (12.5) |
Solid organ neoplasm | 98 (18.5) |
Hematological cancer | 38 (7.2) |
Autoimmune disease | 26 (4.9) |
Diabetes | 138 (26) |
Renal disease | 77 (14.5) |
Liver disease | 24 (4.5) |
Neurological disease | 228 (43) |
Fracture | 40 (7.5) |
Immunosuppression | 77 (14.5) |
Transplant recipient | 5 (0.9) |
Atrial fibrillation | 83 (15.7) |
Age-adjusted Charlson score | 6 [5–7] |
Vaccination status | |
Unvaccinated/partially vaccinated | 220 (41.5) |
Fully vaccinated | 107 (20.2) |
Boosted (> 2 doses) | 198 (37.4) |
Diagnosis | |
Hospital transmission | 108 (20.4) |
Days from diagnosis to admission | 0 [0–4] |
Admission department | |
Infectious Diseases | 326 (61.5) |
Internal Medicine | 167 (31.5) |
Other | 37 (7) |
Clinical information | |
Signs/symptoms | 444 (83.8) |
Cough | 40 (7.5) |
Elevated ferritin | 52 (9.8) |
Lymphopenia | 181 (34.2) |
Hypoxia | 180 (34) |
Shortness of breath | 140 (26.4) |
Fever | 197 (37.2) |
Received treatment | 411 (77.5) |
Oxygen support | |
No oxygen | 97 (18.3) |
Nasal cannula | 49 (9.2) |
Mask | 334 (63) |
HFNC/NIV | 19 (3.6) |
Mechanical ventilation | 26 (4.9) |
Remdesivir treatment | |
No treatment | 237 (44.7) |
3-day prophylaxis | 26 (4.9) |
5-day treatment | 262 (49.4) |
Dexamethasone | 332 (62.6) |
Immunomodulators | |
None | 495 (93.4) |
Tocilizumab | 18 (3.4) |
Anakinra | 6 (1.1) |
Baricitinib | 5 (0.9) |
Nirmatrelvir/ritonavir | 3 (0.6) |
Outcomes | |
Days from admission to death | 8 [4–15] |
Death attributed or related to COVID-19 | 290 (54.7) |
Death not related to COVID-19 | 240 (45.3) |
